Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose), Application (Cancer, Chronic Kidney Disease, Inflammatory Bowel Disease) - Global Forecast 2024-2030

Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Dextran, Iron Sucrose), Application (Cancer, Chronic Kidney Disease, Inflammatory Bowel Disease) - Global Forecast 2024-2030


The Intravenous Iron Drugs Market size was estimated at USD 2.89 billion in 2023 and expected to reach USD 3.16 billion in 2024, at a CAGR 9.65% to reach USD 5.50 billion by 2030.

Global Intravenous Iron Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Intravenous Iron Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Intravenous Iron Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Iron Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc, Actavis, Inc., Allergan, Inc., AMAG Pharmaceuticals. Inc., American Regent. Inc., Baxter International Inc, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Ltd., Fresenius Medical Care AG & Co., Galenica Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pharmacosmos A/S, Rockwell Medical, Inc., Sanofi AG, Shield Therapeutics PLC, and Vifor Pharma Management Ltd..

Market Segmentation & Coverage

This research report categorizes the Intravenous Iron Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Ferric Carboxymaltose

Iron Dextran

Iron Sucrose

Application
Cancer

Chronic Kidney Disease

Inflammatory Bowel Disease

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Intravenous Iron Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Intravenous Iron Drugs Market?
3. What are the technology trends and regulatory frameworks in the Intravenous Iron Drugs Market?
4. What is the market share of the leading vendors in the Intravenous Iron Drugs Market?
5. Which modes and strategic moves are suitable for entering the Intravenous Iron Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Intravenous Iron Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic kidney disease
5.1.1.2. Need for preventing anemia in pregnant women as well as improving maternal and birth outcomes
5.1.1.3. Investment in the healthcare sector, higher spending on medicine
5.1.2. Restraints
5.1.2.1. Stringent regulations with the drug approval process
5.1.3. Opportunities
5.1.3.1. Increasing research in new drug development
5.1.3.2. Improvements in supply chain and distribution network
5.1.4. Challenges
5.1.4.1. Side-effects related to Intravenous Iron drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Intravenous Iron Drugs Market, by Product
6.1. Introduction
6.2. Ferric Carboxymaltose
6.3. Iron Dextran
6.4. Iron Sucrose
7. Intravenous Iron Drugs Market, by Application
7.1. Introduction
7.2. Cancer
7.3. Chronic Kidney Disease
7.4. Inflammatory Bowel Disease
8. Americas Intravenous Iron Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Intravenous Iron Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.
10. South Korea
9.
11. Taiwan
9.
12. Thailand
9.
13. Vietnam
10. Europe, Middle East & Africa Intravenous Iron Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.
10. Nigeria
10.
11. Norway
10.
12. Poland
10.
13. Qatar
10.
14. Russia
10.
15. Saudi Arabia
10.
16. South Africa
10.
17. Spain
10.
18. Sweden
10.
19. Switzerland
10.
20. Turkey
10.
21. United Arab Emirates
10.
22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbott Laboratories Inc
12.1.2. Actavis, Inc.
12.1.3. Allergan, Inc.
12.1.4. AMAG Pharmaceuticals. Inc.
12.1.5. American Regent. Inc.
12.1.6. Baxter International Inc
12.1.7. Bayer AG
12.1.8. Bristol-Myers Squibb Company
12.1.9. Daiichi Sankyo Company, Ltd.
12.1.
10. Fresenius Medical Care AG & Co.
12.1.
11. Galenica Ltd.
12.1.
12. Merck & Co., Inc.
12.1.
13. Novartis AG
12.1.
14. Pfizer, Inc.
12.1.
15. Pharmacosmos A/S
12.1.
16. Rockwell Medical, Inc.
12.1.
17. Sanofi AG
12.1.
18. Shield Therapeutics PLC
12.1.
19. Vifor Pharma Management Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. INTRAVENOUS IRON DRUGS MARKET RESEARCH PROCESS
FIGURE 2. INTRAVENOUS IRON DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. INTRAVENOUS IRON DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INTRAVENOUS IRON DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INTRAVENOUS IRON DRUGS MARKET DYNAMICS
FIGURE 7. INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. INTRAVENOUS IRON DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. INTRAVENOUS IRON DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES INTRAVENOUS IRON DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IRON DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. INTRAVENOUS IRON DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. INTRAVENOUS IRON DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings